Fee(3)Common Stock, $0.01 par value per share7,395,498$6.22$45,999,998$5,332(3)(1)Includes 964,630 shares which the underwriters have the option to purchase from the registrant.(2)Estimated solely for purposes of computing the amount of the registration fee pursuant to Rule 457(a) under the Securities Act of
underwriters an option for a period of 30 days to purchase an additional 964,630 shares of our common stock.Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
With the positive data from this study, we believe this completes the efficacy program for the IV meloxicam new drug application, or NDA.Lead Product Candidate – Injectable MeloxicamMeloxicam is a long-acting, preferential COX-2 inhibitor that possesses anti-inflammatory, analgesic, and antipyretic activities, which are believed to be related to the inhibition of
Our strategy to achieve this goal includes:•Advance IV meloxicam through clinical development and regulatory approval for moderate to severe pain.•Commercialize IV meloxicam in the United States independently or with third parties.•Expand our development, formulation and manufacturing business.•Enter into strategic partnerships to maximize the potential of our product candidates outside of the United States.•Leverage our management and development experience to explore other indications for injectable meloxicam and to develop our other
approval for or commercialize our products outside of the United States, which would limit our ability to realize their full market potential.•We have incurred substantial indebtedness, which could adversely affect our business.•We use third parties to assist with conducting, supervising and monitoring portions of our clinical studies, and if those third parties
The actual offering price per share will be as determined between us and the underwriters at the time of pricing.6Table of ContentsYear ended December 31,Nine months endedSeptember 30,2015201420162015(in thousands, except share and per share data)Statements of Operations Data:Revenue:Manufacturing, royalty and profit sharing revenue$49,284$—$50,260$32,824Research and development revenue2,668—1,7132,375Total revenue51,952—51,97335,199Operating expenses:Cost of sales (excluding amortization of intangible assets)28,054—25,56319,228Research and development12,2817,87423,1757,260General and administrative13,0173,9989,2638,492Amortization of intangible assets1,884—1,9371,238Change in warrant valuation(1,560)—47119Change in contingent consideration valuation5,246—7,7052,586Total operating expenses58,92211,87267,69038,923Operating loss(6,970)(11,872)(15,717)(3,724)Other income (expense):Interest income12112710Interest expense(5,560)(4,273)(4,279)(3,888)Net loss before income taxes(12,518)(16,134)(19,969)(7,602)Income tax benefit15,551—166—Net income (loss)3,033(16,134)(19,803)(7,602)Accretion of redeemable convertible preferred stock—(1,270)——Net income (loss) applicable to common shareholders3,033(17,404)(19,803)(7,602)Basic net income (loss) per common share$0.36$(2.79)$(2.01)$(0.92)Diluted net income (loss) per common share$0.21$(2.79)(2.01)(0.92)Weighted average basic common share outstanding8,491,0256,238,5819,862,5268,243,909Weighted average diluted common share outstanding8,749,2346,238,5819,862,5268,243,909As of September 30, 2016ActualPro 
Forma(1)Pro FormaAs Adjusted(2)(in thousands)Balance Sheet Data:Cash and cash equivalents$24,752$28,37365,253Working capital37,73641,35778,237Total assets146,009149,630186,510Debt (including current portion)(3)24,23624,23624,236Total shareholders’ equity40,63144,25281,132(1)The pro forma column reflects the sale of 500,000 shares of common stock for approximately $3.6 million in net proceeds under the
obtain;•regulatory developments in the United States and foreign countries;•our plans to develop and commercialize our product candidates;•our ability to raise future financing for continued development;•the performance of our third-party suppliers and manufacturers;•our ability to obtain patent protection and defend our intellectual property rights;•our ability to successfully implement our strategy;•our ability to maintain our relationships and contracts with our commercial partners;•our ability to comply with stringent U.S. and foreign government regulation in the manufacture of pharmaceutical products, including
$36.9 million, or $42.5 if the underwriters exercise their option to purchase additional shares in full, assuming an offering price of $6.22 per share, the last reported sales price of our common stock on the Nasdaq Capital Market on December
The actual offering price per share will be as determined between us and the underwriters at the time of pricing.We intend to use the net proceeds from this offering to fund the NDA filing and regulatory approval process and preparatory commercial
In addition to Dex-IN and Dex-SL, we have another selective alpha-2 agonist product candidate in our pipeline, Fadolmidine, or Fado, which we believe also shows promise in neuropathic pain based on preclinical data.17Table of ContentsPipelineCorporate History and Significant Milestones•We were incorporated in 2007, and began operating in 2008.•In March 2014, we closed our IPO in which we sold 4,312,500 shares of common stock for net proceeds of approximately $30.3 million.•In February 2015, we entered into a common stock purchase agreement with Aspire Capital Fund, LLC, or Aspire, under which, as of
price per share of $11.60, for net proceeds of approximately $14.8 million.•In July 2016, we announced positive results from a Phase III pivotal clinical trial evaluating our lead product candidate, injectable
meloxicam, in pain relief over a 48-hour period in a hard tissue, post-operative pain model.•In August 2016, we closed an underwritten public offering in which we sold 1,986,666 shares of common stock at a price per share of
interested in new non-opioid pain therapies that provide effective post-operative pain relief without the adverse issues associated with opioids.20Table of ContentsInjectable Meloxicam AdvantagesWe believe injectable meloxicam has a number of advantages over existing, FDA approved analgesics, including the following:Not considered a controlled substance.Meloxicam is not an opioid and not a controlled substance.
profile in our additional safety study, we anticipate filing an NDA for IV meloxicam in the summer of 2017.21Table of ContentsPhase III Clinical TrialsStudy REC-15-016In July 2016 we announced positive results from one pivotal clinical trial, evaluating pain relief over a 48-hour period in a hard tissue, post-operative pain model (bunionectomy).
In addition, we issued to OrbiMed a seven year warrant to purchase an aggregate of 294,928 shares of our common stock, with an exercise price of $3.28 per share, subject to certain adjustments.Registration RightsPrivate PlacementIn July 2015 we completed a private